Clinical and Commercial Manufacturing: Scalable Global Solutions

Crystal Pharmatech is a premier partner for high-quality, flexible clinical and commercial production. We leverage a robust formulation services platform to help our clients accelerate drug launches through tailored manufacturing strategies and reliable execution.

Comprehensive Dosage Form Expertise

Our manufacturing capabilities are designed to overcome complex solubility and patient-centric challenges across a diverse range of delivery systems:

Oral Solid Dosage Forms

Expert production of tablets, capsules, and sachets.

Bioavailability Enhancement

Specialized spray drying and HME manufacturing for insoluble compounds.

Pediatric Innovation

Advanced manufacturing of mini-tablet to meet unique pediatric clinical needs.

Global CDMO Facilities

We operate state-of-the-art facilities across two continents, providing a seamless transition from specialized research to commercial-scale manufacturing.

Crystal Formulation Services

Suzhou, China · Our flagship 50,590 sq. ft. facility serves as a global hub for manufacturing & clinical distribution

50,590 sq. ft.

GMP Manufacturing

17,250 sq. ft.

facility capable of handling batch sizes up to 120 kg

R&D Center

11,840 sq. ft.

dedicated to science driven-pharmaceutical research

Clinical Supply Depot

21,500 sq. ft.

providing full packaging, labeling, storage, and distribution
with ex-China supported by a partnered U.S., EU and Australia depot

2026 GMP Facility Expansion

By the end of 2026, our production capacity will increase to over 500 kg, transforming our site into a full-scale commercial manufacturing center.

Large-Scale ASD Platform

Installation of a PSD-3 level spray dryer to support high-volume Amorphous Solid Dispersion production.

Commercial Equipment

Addition of >1,000L blenders, Alexanderwerk WP200, Korsh XL400, Freund Vector LDCS Pro units.

End-to-End Solutions

Integration of advanced blister packaging lines for a complete "Molecule-to-Market" solution.

2026 R&D Headquarters Relocation

Our research core—including pre-formulation, formulation development, and analytical testing—is relocating to our global headquarters in 2026.

Doubled Capacity

This move will double our total R&D space, enhancing synergy between analytical and formulation teams.

Consolidated Expertise

Centralizing these units ensures that projects move from development to production with maximum efficiency.

Candoo Pharmatech

Toronto, Canada · Our North American hub provides 12,500 sq. ft. of integrated space to support Western pharmaceutical markets.

12,500 sq. ft.

GMP Facility

9,000 sq. ft.

Supporting batch sizes up to 100 kg

R&D Space

3,500 sq. ft.

Optimized for agile formulation and development

Quality and Audit Excellence: A Proven Partner

Our infrastructure and Quality Management Systems comply with the highest international cGMP standards of the NMPA, FDA, and EMA.

Verified Compliance

As of January 2026, we have successfully completed 31 audits by global Biotech and Pharmaceutical clients, including six from the U.S..

Global Audits

U.S. Client Audits

Verified Jan 2026

Regulatory and Third-party Milestones

NMPA

Certified

Certified for manufacturing

Achieved December 2022

EU QP

Audit Passed

Audit completion

Completed December 2023

FDA

Expected 2H 2026

Inspection triggered by a commercial product manufacture for the US market

Expected 2H 2026

SGS

Inspected

GMP and GDP inspections completed across three consecutive years

3Q2023 · 3Q2024 · 3Q2025

Achieve Your Success with Our Expertise

Have a question or need support with your project? Please complete the form, and our team will get back to you shortly.  

Our capabilities span three specialized platforms:

Small Molecule
Crystal Bio Solutions
Crystal NAX

By providing your e-mail address, you agree to receive an e-mail response from Crystal Pharmatech to your inquiry. The information you submit will be governed by our Privacy Policy.